Docetaxel plus Gemcitabine

PreclinicalSmall molecule

Docetaxel plus Gemcitabine is one of 18 small molecule programs targeting Leiomyosarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeiomyosarcomaActive, not recruiting

LeiomyosarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Leiomyosarcoma

#DrugCompanyPhaseTrials

Femara

Zometa

Adriamycin

6 4

Zepzelca

Jazz Pharmaceuticals

Phase 3

1 5

Yondelis

AApotex Inc.

Phase 3

8 6

Gemzar

Johnson & Johnson

Phase 2

3 7

Rubraca

Bristol-Myers Squibb

Phase 2

1 8

Opdivo

Bristol-Myers Squibb

Phase 2

1 9

Libtayo

Regeneron

Phase 2

1 10

Navmi

SSummit Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leiomyosarcoma1 trial

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00614835·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Docetaxel plus Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel plus Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel plus Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMemorial Sloan Kettering Cancer Center

Docetaxel plus Gemcitabine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leiomyosarcoma1 trial

References

Drug Info

Quick Facts

Related News